Updated EULAR guidelines: Avoid DMARDs in patients with hand osteoarthritis

The European League Against Rheumatism (EULAR) has published updated guidelines for the management of hand osteoarthritis (OA).

 

The guidelines, published in January 2019 issue of Annals of the Rheumatic Diseases give emphasis to shared decision-making and multidisciplinary and multimodal treatment. They also advise against using disease-modifying antirheumatic drugs (DMARDs) given their lack of efficacy in hand OA.

 

The guidelines include five overarching principles and 10 recommendations.

 

Overarching principles

 

  • The primary goal of management is to control symptoms (pain and stiffness) and to optimise hand function (to maximize activity, participation and quality of life).
  • All patients should be offered information on the nature and course of the disease including education on self-management principles and treatment options.
  • Management should be individualized depending on its localization, severity and comorbidities.
  • Management should be based on a shared decision making between the patient and the doctor.
  • A multidisciplinary approach is required for optimal care: Nonpharmacological, pharmacological options and surgery.

 

Recommendations

 

  1. Every patient should be educated and trained in ergonomic principles, pacing of activity, and use of assistive devices.
  2. Exercises to improve function and muscle strength, as well as to reduce pain, should be considered for every patient.
  3. Consider orthoses for symptomatic relief in patients with thumb base OA. Long term use is advocated.
  4. Topical therapy is preferred over systemic therapy. The 1st pharmacological topical treatment of choice is a topical NSAID.
  5. Oral analgesics, particularly NSAIDs, should be considered for a limited duration for symptomatic relief.
  6. Chondroitin sulphate may be used for pain relief and functional improvement.
  7. Intra-articular steroid may be considered in patients with painful interphalangeal joints, but should generally be avoided.
  8. Avoid DMARDs, conventional or biological.
  9. Surgery is indicated in patients with structural abnormalities when other treatment modalities have failed to relieve pain; tapeziectomy in patients with thumb base OA and arthrodesis or arthroplasty in patients with interphalangeal OA.
  10. Long-term follow-up should be as per the individual needs of the patient.

 

(EULAR Press Release)

Be the first to comment

Leave a Reply

Your email address will not be published.


*